
Search Clinical Trials
Below please find a list of studies actively recruiting volunteers at one of the following GHUCCTS institutions: Georgetown University, Howard University, MedStar Health Research Institute, or Washington DC VA Medical Center. Please enter your search criteria below to help find a study for you. If you have any questions, please email us or call us at 301-560-2963.
Study is registered in ResearchMatch ![]() Sponsor Condition of Interest |
---|
Convalescent Plasma to Limit SARS-CoV-2 Associated Complications
![]()
Johns Hopkins University
SARS-CoV 2
To assess the efficacy and safety of Human coronavirus immune plasma (HCIP) to reduce the
risk of hospitalization or death, the duration of symptoms and duration of nasopharyngeal or
oropharyngeal viral shedding.
expand
To assess the efficacy and safety of Human coronavirus immune plasma (HCIP) to reduce the risk of hospitalization or death, the duration of symptoms and duration of nasopharyngeal or oropharyngeal viral shedding. Type: Interventional Start Date: Jun 2020 |
Alzheimer's Disease Neuroimaging Initiative 3 (ADNI3) Protocol
![]()
University of Southern California
Mild Cognitive Impairment (MCI)
Alzheimer's Disease (AD)
Since its launch in 2004, the overarching aim of the Alzheimer's Disease Neuroimaging
Initiative (ADNI) has been realized in informing the design of therapeutic trials in AD.
ADNI3 continues the previously funded ADNI-1, ADNI-GO, and ADNI-2 studies that have been
combined... expand
Since its launch in 2004, the overarching aim of the Alzheimer's Disease Neuroimaging Initiative (ADNI) has been realized in informing the design of therapeutic trials in AD. ADNI3 continues the previously funded ADNI-1, ADNI-GO, and ADNI-2 studies that have been combined public/private collaborations between academia and industry to determine the relationships between the clinical, cognitive, imaging, genetic and biochemical biomarker characteristics of the entire spectrum of Alzheimer's disease (AD). The overall goal of the study is to continue to discover, optimize, standardize, and validate clinical trial measures and biomarkers used in AD research. Type: Observational Start Date: Oct 2016 |
Children With Diabetes at Risk for Heart Disease.
![]()
Georgetown University
Diabetes Mellitus, Type 1
Diabetes Complications
Patients with type 1 diabetes type 1 (DM1) have increased risk of death due to heart disease
and stroke. These cardiovascular conditions (CVD) are the leading cause of death in patients
with DM1 younger than 40 years of age and up to 35% of all persons with DM1 will die before... expand
Patients with type 1 diabetes type 1 (DM1) have increased risk of death due to heart disease and stroke. These cardiovascular conditions (CVD) are the leading cause of death in patients with DM1 younger than 40 years of age and up to 35% of all persons with DM1 will die before age 55 from CVD. Strategies are needed to help identify adolescents with DM1 at risk for CVD so that interventions to prevent heart disease and stroke can be undertaken. Type: Observational Start Date: Oct 2014 |
Transcranial Direct Current Stimulation for Post-stroke Motor Recovery
![]()
Duke University
Stroke, Ischemic
Motor Activity
Upper Extremity Paralysis
This research study is to find out if brain stimulation at different dosage level combined
with an efficacy-proven rehabilitation therapy can improve arm function. The stimulation
technique is called transcranial direct current stimulation (tDCS). The treatment uses direct... expand
This research study is to find out if brain stimulation at different dosage level combined with an efficacy-proven rehabilitation therapy can improve arm function. The stimulation technique is called transcranial direct current stimulation (tDCS). The treatment uses direct currents to stimulate specific parts of the brain affected by stroke. The adjunctive rehabilitation therapy is called "modified Constraint-Induced Movement Therapy" (mCIMT). During this therapy the subject will wear a mitt on the hand of the arm that was not affected by a stroke and force to use the weak arm. The study will test 3 different doses of brain stimulation in combination with mCIMT to find out the most promising one. Type: Interventional Start Date: Sep 2019 |
Memory Improvement Through Nicotine Dosing (MIND) Study
![]()
University of Southern California
Mild Cognitive Impairment
The purpose of the study is to see if daily transdermal nicotine is able to produce a
significant cognitive, clinical and functional improvement in participants with MCI. Neuronal
nicotinic receptors have long been known to play a critical role in memory function in
preclinical... expand
The purpose of the study is to see if daily transdermal nicotine is able to produce a significant cognitive, clinical and functional improvement in participants with MCI. Neuronal nicotinic receptors have long been known to play a critical role in memory function in preclinical studies, with nicotine improving attention, learning, and memory function. The study will enroll 300 participants for a 2 year period. Participants will be randomized (50:50) to either the transdermal nicotine, beginning at 7mg/day, and increasing to 21mg/day, or placebo skin patch. Type: Interventional Start Date: Jan 2017 |
The RADIANCE II Pivotal Study: A Study of the ReCor Medical Paradise System in Stage II Hypertension
![]()
ReCor Medical, Inc.
Hypertension
Vascular Diseases
Cardiovascular Diseases
The objective of the RADIANCE II Pivotal study is to demonstrate the effectiveness and safety
of the Paradise System in subjects with Stage 2 hypertension on 0-2 medications at the time
of consent. Prior to randomization, subjects will be hypertensive in the absence of
hypertension... expand
The objective of the RADIANCE II Pivotal study is to demonstrate the effectiveness and safety of the Paradise System in subjects with Stage 2 hypertension on 0-2 medications at the time of consent. Prior to randomization, subjects will be hypertensive in the absence of hypertension medication. Type: Interventional Start Date: Dec 2018 |
Convalescent Plasma to Stem Coronavirus (CSSC-001)
![]()
Johns Hopkins University
Coronavirus
Convalescence
Evaluate the efficacy of treatment with high-titer Anti- SARS-CoV-2 plasma versus control
(SARS-CoV-2 non-immune plasma) in subjects exposed to Coronavirus disease (COVID-19) at day
28.
expand
Evaluate the efficacy of treatment with high-titer Anti- SARS-CoV-2 plasma versus control (SARS-CoV-2 non-immune plasma) in subjects exposed to Coronavirus disease (COVID-19) at day 28. Type: Interventional Start Date: Jun 2020 |
AHEAD 3-45 Study: A Study to Evaluate Efficacy and Safety of Treatment With Lecanemab in Participants...
![]()
Eisai Inc.
Preclinical Alzheimer's Disease
Early Preclinical Alzheimer's Disease
The primary purpose of this study is to determine whether treatment with lecanemab is
superior to placebo on change from baseline of the Preclinical Alzheimer Cognitive Composite
5 (PACC5) at 216 weeks of treatment (A45 Trial) and to determine whether treatment with
lecanemab... expand
The primary purpose of this study is to determine whether treatment with lecanemab is superior to placebo on change from baseline of the Preclinical Alzheimer Cognitive Composite 5 (PACC5) at 216 weeks of treatment (A45 Trial) and to determine whether treatment with lecanemab is superior to placebo in reducing brain amyloid accumulation as measured by amyloid positron emission tomography (PET) at 216 weeks of treatment (A3 Trial). Type: Interventional Start Date: Jul 2020 |
EMPA-KIDNEY (The Study of Heart and Kidney Protection With Empagliflozin)
![]()
Boehringer Ingelheim
Chronic Kidney Disease
The primary aim of the study is to investigate the effect of empagliflozin on kidney disease
progression or cardiovascular death versus placebo on top of standard of care in patients
with pre-existing chronic kidney disease
expand
The primary aim of the study is to investigate the effect of empagliflozin on kidney disease progression or cardiovascular death versus placebo on top of standard of care in patients with pre-existing chronic kidney disease Type: Interventional Start Date: Jan 2019 |
A Study of Alectinib, Entrectinib, Vemurafenib Plus Cobimetinib, or Pralsetinib in Patients With Resectable...
Genentech, Inc.
Non-small Cell Lung Cancer
This trial will evaluate the efficacy and safety of targeted therapies in participants with
resectable Stage IIA, IIB, IIIA, and select IIIB (T3N2) resectable and untreated non-small
cell lung cancer (NSCLC) tumors with selected molecular alterations.
expand
This trial will evaluate the efficacy and safety of targeted therapies in participants with resectable Stage IIA, IIB, IIIA, and select IIIB (T3N2) resectable and untreated non-small cell lung cancer (NSCLC) tumors with selected molecular alterations. Type: Interventional Start Date: Nov 2020 |
Efficacy, Safety, and Tolerability of Atogepant for the Prevention of Chronic Migraine
Allergan
Chronic Migraine
This study will evaluate the efficacy, safety and tolerability of atogepant in participants
with chronic migraine. This study includes a 12-week treatment period.
expand
This study will evaluate the efficacy, safety and tolerability of atogepant in participants with chronic migraine. This study includes a 12-week treatment period. Type: Interventional Start Date: Mar 2019 |
177Lu Radiolabeled Monoclonal Antibody HuJ591 (177Lu-J591) and Ketoconazole in Patients With Prostate...
Weill Medical College of Cornell University
Prostate Cancer
The purpose of this study is to test the effectiveness of the experimental drug, 177Lu-J591
in combination with ketoconazole and hydrocortisone against prostate cancer.
expand
The purpose of this study is to test the effectiveness of the experimental drug, 177Lu-J591 in combination with ketoconazole and hydrocortisone against prostate cancer. Type: Interventional Start Date: Jun 2009 |
A Study of Tirzepatide (LY3298176) Versus Insulin Lispro (U100) in Participants With Type 2 Diabetes...
Eli Lilly and Company
Type 2 Diabetes
The purpose of this study is to compare the safety and efficacy of the study drug tirzepatide
to insulin lispro (U100) three times a day in participants with type 2 diabetes that are
already on insulin glargine (U100), with or without metformin.
expand
The purpose of this study is to compare the safety and efficacy of the study drug tirzepatide to insulin lispro (U100) three times a day in participants with type 2 diabetes that are already on insulin glargine (U100), with or without metformin. Type: Interventional Start Date: Oct 2020 |
Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene...
National Cancer Institute (NCI)
Recurrent Adrenal Gland Pheochromocytoma
Recurrent Ectomesenchymoma
Recurrent Ependymoma
Recurrent Ewing Sarcoma
Recurrent Hepatoblastoma
This phase II pediatric MATCH trial studies how well tipifarnib works in treating patients
with solid tumors that have recurred or spread to other places in the body (advanced),
lymphoma, or histiocytic disorders, that have a genetic alteration in the gene HRAS.
Tipifarnib... expand
This phase II pediatric MATCH trial studies how well tipifarnib works in treating patients with solid tumors that have recurred or spread to other places in the body (advanced), lymphoma, or histiocytic disorders, that have a genetic alteration in the gene HRAS. Tipifarnib may block the growth of cancer cells that have specific genetic changes in a gene called HRAS and may reduce tumor size. Type: Interventional Start Date: Jul 2020 |
Navigating Insurance Coverage Expansion (NICE)
University of Chicago
HIV/AIDS
The purpose of this research is to measure the effectiveness of an in-person assistance
intervention on successful insurance enrollment, types of insurance coverage, rates of
linkage to and retention in HIV-related health care, referrals to other HIV-associated health
services,... expand
The purpose of this research is to measure the effectiveness of an in-person assistance intervention on successful insurance enrollment, types of insurance coverage, rates of linkage to and retention in HIV-related health care, referrals to other HIV-associated health services, and health outcomes. The study population is Black and Hispanic men who have sex with men (MSM) and transgender persons who are at higher risk for HIV. The study team will be testing the hypotheses that in-person health insurance enrollment assistance results in positive outcomes with regard to linkage to and retention in HIV-related health care. Analyses will be used to assess the efficacy of the intervention as an emerging practice. Type: Interventional Start Date: Oct 2018 |
Amplatzer Amulet LAAO vs. NOAC
Abbott Medical Devices
Atrial Fibrillation
Stroke
Bleeding
The objective of this trial is to evaluate the safety and effectiveness of the Amulet LAA
occluder compared to NOAC therapy in patients with non-valvular AF at increased risk for
ischemic stroke and who are recommended for long-term NOAC therapy.
The clinical investigation... expand
The objective of this trial is to evaluate the safety and effectiveness of the Amulet LAA occluder compared to NOAC therapy in patients with non-valvular AF at increased risk for ischemic stroke and who are recommended for long-term NOAC therapy. The clinical investigation is a prospective, randomized, multicenter active control worldwide trial. Subjects will be randomized in a 1:1 ratio between the Amulet LAA occlusion device ("Device Group") and a commercially available NOAC medication ("Control Group"). The choice of NOAC in the Control Group will be left to study physician discretion. Type: Interventional Start Date: Jul 2020 |
Single Fraction Stereotactic Radiosurgery Compared With Fractionated Stereotactic Radiosurgery in Treating...
Alliance for Clinical Trials in Oncology
Metastatic Malignant Neoplasm in the Brain
This phase III trial studies how well single fraction stereotactic radiosurgery works
compared with fractionated stereotactic radiosurgery in treating patients with cancer that
has spread to the brain from other parts of the body and has been removed by surgery. Single
fraction... expand
This phase III trial studies how well single fraction stereotactic radiosurgery works compared with fractionated stereotactic radiosurgery in treating patients with cancer that has spread to the brain from other parts of the body and has been removed by surgery. Single fraction stereotactic radiosurgery is a specialized radiation therapy that delivers a single, high dose of radiation directly to the tumor and may cause less damage to normal tissue. Fractionated stereotactic radiosurgery delivers multiple, smaller doses of radiation therapy over time. This study may help doctors find out if fractionated stereotactic radiosurgery is better or worse than the usual approach with single fraction stereotactic radiosurgery. Type: Interventional Start Date: Oct 2019 |
Vitamin D3 With Chemotherapy and Bevacizumab in Treating Patients With Advanced or Metastatic Colorectal...
Alliance for Clinical Trials in Oncology
Colorectal Adenocarcinoma
This phase III trial studies how well vitamin D3 given with standard chemotherapy and
bevacizumab works in treating patients with colorectal cancer that has spread to other parts
of the body. Vitamin D3 helps the body use calcium and phosphorus to make strong bones and
teeth.... expand
This phase III trial studies how well vitamin D3 given with standard chemotherapy and bevacizumab works in treating patients with colorectal cancer that has spread to other parts of the body. Vitamin D3 helps the body use calcium and phosphorus to make strong bones and teeth. Drugs used in chemotherapy, such as leucovorin calcium, fluorouracil, oxaliplatin, and irinotecan hydrochloride, work in different ways to stop the growth of tumor cells by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such as bevacizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving vitamin D3 with chemotherapy and bevacizumab may work better in shrinking or stabilizing colorectal cancer. It is not yet known whether giving high-dose vitamin D3 in addition to chemotherapy and bevacizumab would extend patients' time without disease compared to the usual approach (chemotherapy and bevacizumab). Type: Interventional Start Date: Sep 2019 |
Safety, Tolerability, and Efficacy of Cilofexor in Non-Cirrhotic Adults With Primary Sclerosing Cholangitis
Gilead Sciences
Primary Sclerosing Cholangitis
The primary objective of this study is to evaluate whether cilofexor reduces the risk of
fibrosis progression among non-cirrhotic adults with primary sclerosing cholangitis (PSC).
expand
The primary objective of this study is to evaluate whether cilofexor reduces the risk of fibrosis progression among non-cirrhotic adults with primary sclerosing cholangitis (PSC). Type: Interventional Start Date: Mar 2019 |
Use of a Pre-Surgical Toolkit in Improving Surgical Care and Outcomes in Older Participants With Cancer
Alliance for Clinical Trials in Oncology
Malignant Neoplasm
Surgical Procedure, Unspecified
Health Care Provider
Carcinoma
This trial studies how well the use of a pre-surgical toolkit (OPTI-Surg) works in improving
surgical care and outcomes in older participants with cancer. In many elderly patients,
surgery can greatly affect physical condition and the ability to return to pre-surgery levels... expand
This trial studies how well the use of a pre-surgical toolkit (OPTI-Surg) works in improving surgical care and outcomes in older participants with cancer. In many elderly patients, surgery can greatly affect physical condition and the ability to return to pre-surgery levels of physical functioning. Providing pre-surgical recommendations may help improve participants' recovery rate and functioning after surgery. Type: Interventional Start Date: Apr 2019 |
An Open-Label Extension Study to Evaluate Long-Term Safety and Tolerability of RO7234292 (RG6042) in...
Hoffmann-La Roche
Huntington Disease
This study will evaluate the long-term safety and tolerability of RO7234292 (RG6042) in
participants who have completed other F. Hoffmann-La Roche, Ltd.-sponsored and/or
Genentech-sponsored studies in the Huntington's disease (HD) in the development program for
RG6042.... expand
This study will evaluate the long-term safety and tolerability of RO7234292 (RG6042) in participants who have completed other F. Hoffmann-La Roche, Ltd.-sponsored and/or Genentech-sponsored studies in the Huntington's disease (HD) in the development program for RG6042. Type: Interventional Start Date: Apr 2019 |
A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab...
Hoffmann-La Roche
Cancer
This is an open-label, multicenter, extension study. Patients who are receiving clinical
benefit from atezolizumab monotherapy or atezolizumab in combination with other agent(s) or
comparator agent(s) during participation in a Genentech or Roche-sponsored study (the parent... expand
This is an open-label, multicenter, extension study. Patients who are receiving clinical benefit from atezolizumab monotherapy or atezolizumab in combination with other agent(s) or comparator agent(s) during participation in a Genentech or Roche-sponsored study (the parent study), who are eligible to continue treatment and who do not have access to the study treatment locally, may continue to receive study treatment in this extension study following roll-over from the parent study. Type: Interventional Start Date: Feb 2019 |
Efficacy and Safety of Olaparib (MK-7339) in Participants With Previously Treated, Homologous Recombination...
Merck Sharp & Dohme Corp.
Advanced Solid Neoplasms
This study will evaluate the efficacy and safety of olaparib (MK-7339) monotherapy in
participants with multiple types of advanced cancer (unresectable and/or metastatic) that: 1)
have progressed or been intolerant to standard of care therapy; and 2) are positive for
homologous... expand
This study will evaluate the efficacy and safety of olaparib (MK-7339) monotherapy in participants with multiple types of advanced cancer (unresectable and/or metastatic) that: 1) have progressed or been intolerant to standard of care therapy; and 2) are positive for homologous recombination repair mutation (HRRm) or homologous recombination deficiency (HRD). Type: Interventional Start Date: Dec 2018 |
Edwards PASCAL CLASP IID/IIF Pivotal Clinical Trial
Edwards Lifesciences
Degenerative Mitral Valve Disease
Mitral Regurgitation
Mitral Insufficiency
Functional Mitral Regurgitation
To establish the safety and effectiveness of the Edwards PASCAL Transcatheter Valve Repair
System in patients with degenerative mitral regurgitation (DMR) who have been determined to
be at prohibitive risk for mitral valve surgery by the Heart Team, and in patients with
functional... expand
To establish the safety and effectiveness of the Edwards PASCAL Transcatheter Valve Repair System in patients with degenerative mitral regurgitation (DMR) who have been determined to be at prohibitive risk for mitral valve surgery by the Heart Team, and in patients with functional mitral regurgitation (FMR) on guideline directed medical therapy (GDMT) Type: Interventional Start Date: Nov 2018 |
A Phase Ib/II Study Investigating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab...
Hoffmann-La Roche
B-cell Non-Hodgkin Lymphoma
This study will evaluate the safety, pharmacokinetics, and preliminary efficacy of
mosunetuzumab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone
(M-CHOP) and, subsequently, in combination with cyclophosphamide, doxorubicin, and prednisone
(CHP)... expand
This study will evaluate the safety, pharmacokinetics, and preliminary efficacy of mosunetuzumab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone (M-CHOP) and, subsequently, in combination with cyclophosphamide, doxorubicin, and prednisone (CHP) plus polatuzumab vedotin (CHP-pola) in participants with relapsed or refractory (R/R) B-cell non-Hodgkin lymphoma (NHL), and in previously untreated participants with diffuse large B-cell lymphoma (DLBCL). Type: Interventional Start Date: Feb 2019 |